In saphenous vein graft lesions, 1st and 2nd generation DES have similar outcomes

Long-Term Outcomes with First vs. Second-Generation Drug-Eluting Stents in Saphenous Vein Graft Lesions. Nagendra R. Pokala. Catheterization and cardiovascular Intervention 2016;87:34-40

Courtesy of del Dr. Carlos Fava.

Second generation DES have been proved superior to first generation DES in native arteries, but there is limited information on DES in saphenous vein grafts (SVG), from a few small studies.

This study included 81 patients receiving first generation DES and 166 receiving second generation DES.

There were no differences in both populations, with the exception of more frequent unstable angina in the first generation group.

In the first generation cohort, stenting was more frequent on SVG, and in the second generation cohort, on the anastomosis. Distal protection was more frequent in the second generation cohort.

The procedure had similar success in both groups, with a very low complications rate.

Over 41 months follow up, there were no differences in the combined primary end point of death, MI or revascularization (43.5% vs. 40.87%; p= 0.707).

Looking at each of the factors separately, researchers observed a similar events rate in both groups (death 20.91% vs. 20.27%; p=0.916, target lesion revascularization 16.39% vs. 20.00%; p= 0.572, vessel revascularization 20.97% vs. 23.16%; p= 0.747 and AMI 26.15% vs. 23.00% respectively; p= 0.644). Neither were there significant differences in stent thrombosis rates.

Conclusion
First and second generation DES outcomes in saphenous vein grafts are similar. New designs are needed to improve the evolution of this challenging group of patients.

Editorial Comment
DES have been designed for native arteries with arteriosclerosis. Saphenous vein grafts have a rather different structure and disease, with a higher risk of embolism.

It is necessary to develop stents especially designed for SVG to be able to reduce MACE to comparable levels of native vessel stenting.

Courtesy of del Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Argentina

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...